|Bid||17.950 x 680400|
|Ask||18.000 x 298300|
|Day's Range||17.95 - 17.98|
|52 Week Range||17.95 - 17.98|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cerecor, Inc. today announced that its Board of Directors has appointed Peter Greenleaf as Chief Executive Officer. Mr. Greenleaf has served on the Company's board since May 2017. He brings to Cerecor ...
NEW YORK , Feb. 6, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: S&P SmallCap 600 constituent Boyd Gaming Corp. (NYSE:BYD) will ...
Mallinckrodt PLC (NYSE: MNK ) agreed to buy Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP ) in a deal announced in December. The Analyst Weighing in the planned acquisition, Barclays analyst Douglas Tsao ...
The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.
Moody's Investors Service ("Moody's") confirmed Mallinckrodt International Finance SA's ("Mallinckrodt") Corporate Family Rating ("CFR") at Ba3 and Probability of Default ...
The Committee for Medicinal Products for Human Use passes a positive viewpoint on Glaxo's (GSK) shingles vaccine, Shingrix. A final decision from the EU is awaited in April 2018.
NEW YORK, Jan. 25, 2018 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States Central District Court of Maryland, case no. 8:18-cv-00173, on behalf of stockholders of Sucampo Pharmaceuticals, Inc. ("Sucampo" or the "Company") (NASDAQ: SCMP) who held Sucampo securities and have been harmed by Guidance and its board of directors' (the "Board") for alleged violations of Sections 14(d)(4), 14(e), and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the tender offer of Company common stock to be purchased by Mallinckrodt plc ("Mallinckrodt"). Click here for more information: www.monteverdelaw.com/investigations/m-a/ It is free and there is no cost or obligation to you.
Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.
Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.
Anthera (ANTH) posts positive results from the second interim futility analysis of Sollpura for EPI. Top-line data from the study is expected in the first quarter of 2018.
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Sucampo Pharmaceuticals, Inc.
NEW YORK , Jan. 21, 2018 /PRNewswire/ -- Advanced Micro Devices (AMD) Lifshitz & Miller announces investigation into possible securities law violations by AMD and certain of its officers in connection ...
Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.
Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.
Endo International (ENDP) lost 35% in the past year mired by controversy related to Opana ER and weaknesses in both the businesses.
The FDA panel votes against the approval of Aradigm's (ARDM) Linhaliq for treatment of non-cystic fibrosis bronchiectasis. A response from the regulatory agency is expected on Jan 26, 2018.
Endo (ENDP) announced that it received a subpoena from the Florida authorities in connection with products related to opioid misuse.
Adamas (ADMS) shares climb on the commercial launch of Gocovri in the United States for treating dyskinesia in patients with Parkinson's disease. This is the first FDA approved drug for the ailment.
Acorda (ACOR) announces preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for Q4. The company's net sales expectations are higher year over year.